Literature DB >> 17109384

Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study.

Tania M Welzel1, Lene Mellemkjaer, Gridley Gloria, Lori C Sakoda, Ann W Hsing, Laure El Ghormli, Jorgen H Olsen, Katherine A McGlynn.   

Abstract

Recently, the incidence of intrahepatic cholangiocarcinoma (ICC) has been increasing in a number of developed (Western) countries. However, risk factors in these low-risk populations are poorly understood. In this nationwide population based case-control study in Denmark, we examined the relationship between selected medical conditions and subsequent ICC risk to provide additional clues to etiopathogenesis. All histologically confirmed ICC cases diagnosed in Denmark between 1978 and 1991 were identified from the Danish cancer registry. Population controls were selected from the central population registry and were matched 4:1 to cases on sex and year of birth. Cases and controls were linked to the Danish hospital discharge registry to obtain information on prior hospital diagnoses. Odds ratios (OR) and 95% confidence intervals (95% CI) were derived using conditional logistic regression. A total of 764 ICC cases and 3,056 population controls were included in the study. Chronic liver diseases were significantly related to ICC: alcoholic liver disease (OR = 19.22, 95% CI = 5.55-66.54), unspecified cirrhosis (OR = 75.9, 95% CI 10.2-565.7). Bile duct diseases were also associated with risk: cholangitis (OR = 6.3, 95% CI = 2.3-17.5), choledocholithiasis (OR = 23.97, 95% CI = 2.9-198.9), cholecystolithiasis (OR = 4.0, 95% CI = 2.0-7.99), though gallbladder removal did not change risk (OR = 1.6, 95% CI = 0.65-3.7). Among other conditions, chronic inflammatory bowel disease (OR = 4.7, 95% CI = 1.65-13.9) was significantly associated with ICC. Diabetes was associated with risk in the year prior to diagnosis of ICC (OR = 3.02, 95% CI = 1.05-8.69). Obesity was unrelated to risk. These results confirm that prior bile duct diseases increase risk of ICC and suggest that alcoholic liver disease and diabetes may also increase risk.

Entities:  

Mesh:

Year:  2007        PMID: 17109384     DOI: 10.1002/ijc.22283

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  74 in total

Review 1.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.

Authors:  William C Palmer; Tushar Patel
Journal:  J Hepatol       Date:  2012-03-13       Impact factor: 25.083

2.  Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index.

Authors:  Mirna H Farhat; Ali I Shamseddine; Ayman N Tawil; Ghina Berjawi; Charif Sidani; Wael Shamseddeen; Kassem A Barada
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

Review 3.  Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis.

Authors:  Shun-ichi Ariizumi; Masakazu Yamamoto
Journal:  Surg Today       Date:  2014-09-25       Impact factor: 2.549

4.  Obesity and the risk of cholangiocarcinoma: a meta-analysis.

Authors:  Jun-Shan Li; Tian-Jie Han; Nie Jing; Lei Li; Xiao-Hua Zhang; Feng-Zhen Ma; Ji-Yong Liu
Journal:  Tumour Biol       Date:  2014-04-13

5.  Anthropometric Risk Factors for Cancers of the Biliary Tract in the Biliary Tract Cancers Pooling Project.

Authors:  Sarah S Jackson; Alison L Van Dyke; Bin Zhu; Ruth M Pfeiffer; Jessica L Petrick; Hans-Olov Adami; Demetrius Albanes; Gabriella Andreotti; Laura E Beane Freeman; Amy Berrington de González; Julie E Buring; Andrew T Chan; Yu Chen; Gary E Fraser; Neal D Freedman; Yu-Tang Gao; Susan M Gapstur; J Michael Gaziano; Graham G Giles; Eric J Grant; Francine Grodstein; Patricia Hartge; Mazda Jenab; Cari M Kitahara; Synnove F Knutsen; Woon-Puay Koh; Susanna C Larsson; I-Min Lee; Linda M Liao; Juhua Luo; Emma E McGee; Roger L Milne; Kristine R Monroe; Marian L Neuhouser; Katie M O'Brien; Ulrike Peters; Jenny N Poynter; Mark P Purdue; Kim Robien; Dale P Sandler; Norie Sawada; Catherine Schairer; Howard D Sesso; Tracey G Simon; Rashmi Sinha; Rachael Z Stolzenberg-Solomon; Shoichiro Tsugane; Renwei Wang; Elisabete Weiderpass; Stephanie J Weinstein; Emily White; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Xuehong Zhang; Katherine A McGlynn; Peter T Campbell; Jill Koshiol
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

Review 6.  [Diagnostics and treatment of cholangiocellular carcinoma].

Authors:  L Zender; N P Malek
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

Review 7.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 8.  Obesity and cholangiocarcinoma.

Authors:  Mansour A Parsi
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

9.  Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Authors:  Alison L Van Dyke; Meredith S Shiels; Gieira S Jones; Ruth M Pfeiffer; Jessica L Petrick; Jennifer L Beebe-Dimmer; Jill Koshiol
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

10.  Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.

Authors:  Ben-Dong Chen; Wen-Chao Zhao; Jian-Da Dong; Hui Sima
Journal:  Mol Biol Rep       Date:  2014-02-28       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.